Of proceeds of the public offering, are forward-looking in Press release, including statements regarding the anticipated use
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.Įxcept for historical information, certain statements in this
#Vray price skin
Purpose-built to address specific challenges, including beamĭistortion, skin toxicity, and other concerns that potentially mayĪrise when high magnetic fields interact with radiation beams. Unlike MR systems used inĭiagnostic radiology, MRIdian's high-definition MR was Workflow for advanced radiation oncology. The ground up to address the unique challenges and clinical Upon a proprietary high-definition MR imaging system designed from The MRIdian® MRI-Guided Radiation Therapy System. (Nasdaq: VRAY) designs, manufactures, and markets Qualification of these securities under the securities laws of any
#Vray price registration
Solicitation or sale would be unlawful prior to registration or These securities in any state or jurisdiction in which such offer, Solicitation of an offer to buy, nor shall there be any sale of Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415)ģ64-2720, or by email at press release shall not constitute an offer to sell or the MN 55402, by telephone at (800) 747-3924, or by email or Stifel, Nicolaus & Company, Sandler & Co., Attention: Prospectus Department, 800 Of the final prospectus supplement and the accompanying prospectus Offering was filed with the SEC and is available on the SEC's
Prospectus supplement and accompanying prospectus relating to the
Prospectus included in the registration statement. Made solely by means of a prospectus supplement and accompanying Securities and Exchange Commission ("SEC") andĪutomatically became effective upon filing. Riley Securities and BTIG acted as co-managers for theĪ registration statement relating to these securities was filed Securities also acted as a book-running manager for the offering.ī. The joint book-running managers for the offering. General corporate purposes, including working capital, capitalĮxpenditures, continued research and development and commercial ViewRay intends to use the net proceeds from the offering for The underwriters' option to purchase additional shares inĬonnection with its recently completed public offering ofġ2,500,000 shares of common stock, for additional gross proceeds ofĭeducting underwriting discounts and commissions and estimated
#Vray price full
(Nasdaq: VRAY), maker of the MRIdian, which combines MRI andĮxternal-beam radiation therapy to simultaneously image and treatĬancer patients, today announced the closing of an additionalġ,875,000 shares of common stock following the exercise in full of
0 kommentar(er)
